Back to Search Results
Back to Results
Melanoma / Skin
General Information
Study Name:
Pilot Study of Neoantigen Profiling in Patients with Melanoma Treated
with PD-1 Blockade
Age Group:
Adult
Protocol Number:
16-2427
Background Information:
This research study is designed to better understand the molecular determinants of response to immunotherapies including pembrolizumab and nivolumab. We hope to learn the relevance of tumor neoantigens in the recognition of cancer cells by the immune system. The ultimate goal is to rank and filter these neoantigens and correlate with response to immunotherapies.
Offered at:
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
>= 18 years
Stage III or IV melanoma
Underwent treatment with anti-PD-1 therapy (pembrolizumab or nivolumab) for at least 12 weeks with available radiologic response data
For patients prospectively consenting able to provide informed consent for blood collection
For patients eligible but deceased, a waiver of consent is requested to obtain only existing tissue previously collected for clinical purposes
Ineligibility Information
Contact Information
Contact Name:
Kelly Jeffords, CCRP
Contact Phone:
571-472-0631
Contact Email:
kelly.jeffords@inova.org